Quote Overview

Stock Activity

Open	881.72
Day Low	875.23
Day High	887.48
52 Wk Low	684.81
52 Wk High	998.33
Avg. Volume	431,865
Market Cap	97.76 B
Dividend	NA
Beta	0.11

Key Earnings Data

Earnings ESP	-0.79%
Most Accurate Est	10.01
Current Qtr Est	10.09
Current Yr Est	45.35
Exp Earnings Date	^*BMO5/2/24
Prior Year EPS	43.79
Exp EPS Growth (3-5yr) 8.97%
Forward PE	19.64
PEG Ratio	2.19

Medical » Medical - Biomedical and Genetics

*BMO = Before Market Open *AMC = After Market Close

Research Reports for REGN

All Zacks’ Analyst Reports

Premium Research for REGN

Style Scores C Value D Growth A Momentum C VGM
Zacks Rank	Buy 2
Zacks Industry Rank	Top 30%(75 out of 252)
Zacks Sector Rank	Top 25% (4 out of 16)
Earnings ESP	-0.79%
Research Reports for REGN Analyst \| Snapshot

( = Change in last 30 days)

View All Zacks Rank #1 Strong Buys

Premium Research: Industry Analysis

Top Peers	Symbol	Zacks Rank
Regeneron Pharmaceuticals	REGN
ADMA Biologics	ADMA
ANI Pharmaceuticals	ANIP
Basilea Pharmaceutica	BPMUF
Cytek Biosciences	CTKB
Entera Bio	ENTX
Enveric Biosciences	ENVB

See all Medical - Biomedical and Genetics Peers

Zacks News for REGN

No Record found.

Company Summary

Tarrytown, NY-based Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting severe medical conditions. The company’s portfolio boasts of Eylea (for several eye diseases), partnered drug Dupixent (asthma, atopic dermatitis and chronic rhinosinusitis with nasal polyposis), Praluent (heterozygous familial hypercholesterolemia), Kevzara (moderately-to-severely active rheumatoid arthritis), Libtayo (lung cancer), Evkeeza (homozygous familial hypercholesterolemia), Inmazeb (Ebola), Veopoz (CHAPLE disease), Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV, which significantly boosted sales in 2021.

Regeneron has a collaboration agreement with Bayer to co-develop and commercialize co-formulated combinations of Eylea and Eylea HD (aflibercept 8 mg). The company has collaborated with Sanofi on the global development and commercialization of Dupixent, Kevzara and itepekimab. In 2019, Regeneron and Alnylam entered into a global, strategic collaboration to discover, develop and commercialize RNA interference ("RNAi") therapeutics for a broad range of diseases by addressing therapeutic disease targets expressed in the eye and central nervous system ("CNS"), in addition to a select number of targets expressed in the liver.

In 2016, Regeneron collaborated with Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development. The agreement was expanded in 2020 to jointly develop potential products for the treatment of hemophilia A and B. Both companies further expanded the deal to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases.

In April 2024, Regeneron acquired all oncology and autoimmune research and development programs and hired approximately 160 employees from 2seventy bio as part of its newly launched cell medicines business.

Regeneron’s revenues comprise collaboration revenues, net product sales and technology licensing and other revenues. Revenues in 2023 were $13.1 billion, up 8% from 2022. Eylea sales came in at $5.7 billion in the United States.